SG3 Management’s Cytokinetics CYTK Stock Holding History

SG3 Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,000	Closed	-$314K	–	331
2022 Q2	$314K	Sell	8,000 -9,500	-54%	-$382K	0.04%	243
2022 Q1	$644K	Buy	+17,500	New	+$622K	0.02%	550

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SG3 Management's CYTK Position: Q3 2022 in Review

SG3 Management sold out of Cytokinetics (CYTK) in Q3 2022, closing a stake of 8,000 shares — an estimated $314K sold.

SG3 Management first reported a position in CYTK in Q1 2022 and held it in 2 quarters. The position peaked at $644K in Q1 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q3 2022.

SG3 Management reported no remaining Cytokinetics position as of Q3 2022 after selling out during the quarter.
SG3 Management sold 8,000 Cytokinetics shares in Q3 2022, an estimated $314K.
SG3 Management first reported a position in Cytokinetics in Q1 2022 and held it in 2 quarters.
SG3 Management's Cytokinetics position peaked at $644K in Q1 2022.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.